J. Kevin Buchi

Board Director Impax Laboratories

Photograph of J. Kevin Buchi  Mr. Buchi serves as Board Director of Impax Laboratories. He previously served as the Interim President and Chief Executive Officer of Impax. Mr. Buchi was formerly the President, Chief Executive Officer and a member of the board of directors of TetraLogic Pharmaceuticals Corporation,  before its asset sale to Medivir AB.  Prior to joining TetraLogic Pharmaceuticals in August 2013, Mr. Buchi served as Corporate Vice President of Global Branded Products at Teva Pharmaceutical Industries Limited from 2011 to May 2012. Before joining Teva, he was Chief Executive Officer of Cephalon, Inc., which was acquired by Teva in October 2011. Mr. Buchi joined Cephalon in 1991 and held various leadership positions, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon’s Chief Executive Officer in December 2010. In addition to serving as a director of Impax and TetraLogic Pharmaceuticals, Mr. Buchi has since 2013 served as a director of Benitec Biopharma Ltd., a NASDAQ listed biotechnology company headquartered in Australia. He has extensive experience as a director having previously served on the board of more than a dozen pharmaceutical companies including EPIRUS Biopharmaceuticals, Inc., Alexza Pharmaceuticals, Inc. and Forward Pharma A/S. Mr. Buchi received his B.A. degree in Chemistry from Cornell University and a Masters of Management degree from the J.L. Kellogg Graduate School of Management, Northwestern University.